Maravai LifeSciences Holdings, Inc. reports recurring developments as a life sciences supplier of reagents and services for drug therapy, diagnostics, vaccine and human disease research. Company updates center on its TriLink nucleic acid synthesis business, including mRNA, oligonucleotides and CleanCap-related technologies, and its Cygnus biologics safety testing business, including host cell protein ELISA kits, impurity detection assays, reagents and services.
News about MRVI commonly covers quarterly financial results, segment revenue trends, guidance, restructuring and operating cost initiatives, investor conference participation, executive and board changes, and product or commercial updates tied to researchers, biotech innovators, vaccine developers, diagnostics companies and cell and gene therapy customers.
On November 8, 2021, New England Biolabs (NEB) announced the release of the HiScribe T7 mRNA Kit featuring TriLink's CleanCap Reagent AG. This new kit simplifies mRNA synthesis, offering high yields with a Cap 1 structure, enhancing biological activity while reducing immunogenicity. NEB's kits are scalable for therapeutic mRNA manufacturing, including vaccine production. The collaboration aims to accelerate research and development in mRNA technology. NEB continues to expand its offerings in molecular biology, supporting global vaccine programs.
Maravai LifeSciences (NASDAQ: MRVI) has announced its participation in two upcoming virtual investor conferences in November 2021. CFO Kevin Herde will engage in a fireside chat at the Stifel Healthcare Conference on November 17 at 10:20 a.m. PT and present at the Nasdaq Investor Conference on November 30 at 7:00 a.m. PT. Live webcasts will be available on the company's investor relations website, with archived versions posted shortly after each event. Maravai specializes in life science reagents and services, supporting drug therapy and diagnostics development.
Maravai LifeSciences (NASDAQ: MRVI) will announce its third quarter 2021 financial results after market close on November 10, 2021. A conference call is scheduled for 2:00 p.m. PT / 5:00 p.m. ET the same day, which can be accessed by dialing (833) 693-0536 or (661) 407-1576 with conference ID 9136747. Participants can also listen via live or archived webcast on the company's Investors website. Maravai provides essential products for drug therapy, diagnostics, and vaccine development.
Maravai LifeSciences (NASDAQ: MRVI) has announced that its subsidiary, TriLink BioTechnologies, received a new European patent (No. 3352584) for its CleanCap technology, which enhances the production of synthetic mRNA. This patent is crucial for developing mRNA vaccines and therapeutics, facilitating a streamlined manufacturing process that reduces time and costs. Mike Houston, Chief Scientific Officer, highlighted the advantages of CleanCap in improving the efficiency and viability of mRNA constructs, particularly in rapid vaccine responses and personalized cancer therapies.
TriLink BioTechnologies announced its collaboration with EyeGene to supply its proprietary CleanCap® technology and modified uridine triphosphate for the production of EyeGene’s EG-COVID mRNA vaccine, which has received approval for clinical trials from South Korea's MFDS. This partnership marks a significant advancement in mRNA vaccine development, aiming to enhance safety and effectiveness. The vaccine will undergo Phase 1/2a trials, utilizing a cationic liposome delivery system.
Maravai LifeSciences Holdings (NASDAQ: MRVI) announced a public offering of 20 million shares at $50.00 each, set to close on September 14, 2021. The shares are being sold by certain stockholders, with a 30-day option for underwriters to purchase an additional 3 million shares. Maravai will not receive any proceeds from this sale. Key financial institutions such as Morgan Stanley, Jefferies, and Goldman Sachs are managing the offering. The registration statement was declared effective on September 9, 2021.
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) announced a public offering of 20 million Class A shares by selling stockholders, with an option for underwriters to purchase an additional 3 million shares. The company will not receive proceeds from this offering, which is under a registration statement filed with the SEC. Morgan Stanley, Jefferies, and Goldman Sachs are managing the offering. The registration statement is pending effectiveness, and no sales can occur until it is active.
Maravai LifeSciences (NASDAQ: MRVI) will participate in two virtual investor conferences in September 2021. CEO Carl Hull is set to engage in a fireside chat at the Morgan Stanley Healthcare Conference on September 13 at 12:30 p.m. PT, followed by CFO Kevin Herde's presentation at the Baird Global Healthcare Conference on September 14 at 9:50 a.m. PT. Live webcasts will be accessible on the Maravai investor relations website, with archived versions available shortly after each event.
Thompson Street Capital Partners has acquired Vector Laboratories, part of Maravai, enhancing its presence in the life sciences sector. Vector specializes in labeling and visual detection reagents for academic and corporate research. The acquisition aims to leverage TSCP's expertise to foster growth and capitalizes on market opportunities. CEO Lisa V. Sellers highlighted TSCP's role in enhancing Vector’s operations. The deal is expected to propel Vector's strategic and organic growth in a competitive environment.
Maravai LifeSciences reported a remarkable revenue increase of 364.3% year-over-year, totaling $217.8 million for Q2 2021. Net income reached $134.3 million, significantly up from $1.4 million in the prior year. The company raised its full-year revenue guidance to $745 million - $770 million. Key growth drivers included a 532.8% increase in Nucleic Acid Production revenue, alongside the divestiture of its Protein Detection segment for $124 million. Expansion plans for facilities are underway to enhance production capabilities in response to rising demand.